论文部分内容阅读
目的探讨曲美他嗪(TMZ)对应用表阿霉素(EPI)后患者的心肌保护作用。方法应用EPI后1个月内出现心肌受损的患者42例,随机分为盐酸曲美他嗪组(治疗组)和对照组,比较2组1个月后血清肌钙蛋白I(cTnI)、G-反应蛋白(CRP)及左室射血分数(LVEF)的变化。结果治疗组和对照组患者治疗后cTnI分别为[(0.57±0.07)mg/L vs(1.12±0.08)mg/L],CRP浓度分别为[(4.9±1.2)mg/L vs (8.8±4.2)mg/L];LVEF分别为[(52±3)% vs(41±2)%],2组比较差异有统计学意义(P<0.05)。结论TMZ可明显改善应用EPI后患者的心功能,抑制cTnI和CRP浓度的升高。
Objective To investigate the myocardial protective effect of trimetazidine (TMZ) on epirubicin (EPI) patients. Methods Forty-two patients with myocardial damage within 1 month after EPI were randomly divided into trimetrexed hydrochloride group (treated group) and control group. The levels of cTnI, Changes of G-reactive protein (CRP) and left ventricular ejection fraction (LVEF). Results The cTnI of the patients in the treatment group and the control group was [(0.57 ± 0.07) mg / L vs (1.12 ± 0.08) mg / L], and the CRP concentrations were [4.9 ± 1.2 mg / L vs 8.8 ± 4.2 ) mg / L]; LVEF was (52 ± 3)% vs (41 ± 2)%, respectively. There was significant difference between the two groups (P <0.05). Conclusion TMZ can obviously improve the cardiac function of patients after EPI and inhibit the increase of cTnI and CRP concentrations.